Resmetirom, the first approved drug for the management of metabolic dysfunction-associated steatohepatitis: Trials, opportunities, and challenges
Year: 2024
Type: article
Abstract: Over the past decade, there have been several guideline updates for the diagnosis and management of non-alcoholic fatty liver disease (NAFLD), which is the most common chronic liver disease affecting approximately one-third of the world's population [ 1–3 ]. These changes were necessitated by our evolving understanding of the disease, the name of which has also recently been changed from “NAFLD”, resulting from a lack of mechanistic understanding, to metabolic dysfunction-associated steatotic liver disease (MASLD), and from non-alcoholic steatohepatitis (NASH) to metabolic dysfunction-associated steatohepatitis (MASH) [ 4–6 ].
Source: Metabolism
Institutions: Beth Israel Deaconess Medical Center, University Medical Center Groningen, Harvard University, University of Groningen, University of Missouri, Aristotle University of Thessaloniki, Papageorgiou General Hospital, University of California San Diego, Virginia Commonwealth University, Virginia Commonwealth University Medical Center, VA Boston Healthcare System
Language: English
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $5,180
Funders: Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, Gilead Sciences, Alnylam Pharmaceuticals, Regeneron Pharmaceuticals, Massachusetts Life Sciences Center, Arrowhead Pharmaceuticals, Boston Pharmaceuticals, Coherus Biosciences, Novo Nordisk, Universitair Medisch Centrum Groningen, LG Chem, Esperion Therapeutics, National Institutes of Health, Genentech, National Institute on Alcohol Abuse and Alcoholism, National Heart, Lung, and Blood Institute, National Institute of Diabetes and Digestive and Kidney Diseases, National Center for Advancing Translational Sciences
Awards: A Cardiovascular-NASH disease nexus: Common Mechanisms and Treatments?, Non-invasive screening of diabetics for advanced fibrosis due to NAFLD, Novel IL-23 inhibitor for the treatment of alcohol associated liver disease, Ancillary Studies of NAFLD and NASH in HIV infected Adults, QUS Technology for Diagnosis and Grading of Hepatic Steatosis in NAFLD, UC San Diego Clinical and Translational Research Institute, San Diego Digestive Diseases Research Center, Clinical Research on Nonalcoholic Fatty Liver Disease, San Diego Cirrhosis Clinical Research Network
OpenAlex ID: W4392970898